Surveillance MRI Registry for Patients Who Had Breast Cancer With Dense Breast Tissue

Overview

To create a registry (database) of participants who come in for breast MRI scans. Researchers want to use this information to study if participants with dense breast tissue (tissue that is more difficult to see on mammogram).

Detailed description

Primary Objectives

\- To determine the number of false positive biopsies obtained from surveillance MRI in participant with personal history of breast cancer, age 50 or under, and mammographically dense breasts.

Secondary Objectives

I. To determine the incidence of interval cancer.

II. To compare participants with personal history of breast cancer, age 50 and under, who did not receive surveillance MRI.

III. To determine positive predictive value (PPV) and negative predictive value (NPV) of surveillance breast MRI in this population.

IV. To compare the tumor biology of breast cancer detected on breast MRI.

V. To determine the participants experience with MRI i.e. willingness to return for testing with breast MRI.

VI. To evaluate the reasons women refuse breast MRI for the surveillance of recurrent disease or secondary breast cancer.

VII. To determine the patients' interest in having procedural hypnosis to improve patient reported acceptance of breast MRI among participants.

Interventions

• Behavioral Questionnaire/Interview
  Participation on this study will be over as soon as you complete the questionnaire/interview after your scheduled scans.

Primary outcome measures

• Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0 [Time frame: through study completion; an average of 1 year]

Eligibility criteria

Inclusion criteria

• Participants 50 years of age or younger who has personal history of breast cancer and mammographically dense breast, per ACR Category C and D.
• Participants must be 18 years of age or older.
• Participants are being seen at MD Anderson for annual surveillance and scheduled for routine screening mammogram and/or DBT, with negative or benign findings.
• Participants must not be pregnant or breast-feeding. If a Participant is of childbearing potential and is uncertain if the Participant could be pregnant or may be pregnant or as per local site standard of practice in women undergoing mammogram/DBT and MRI must have a blood test or urine study within 2 weeks prior to randomization to rule out pregnancy. A female of childbearing potential is any woman, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months).
• The Participants breast density must be known based on prior mammogram or agree to have mammogram or DBT prior to enrollment in order to determine breast density. Participants must have mammographically dense breasts based on American College of Radiology \[ACR\] Breast Imaging \[BI\]- Reporting and Data System Atlas (RADS) lexicon categories c or d (heterogeneous or extreme fibroglandular tissue) on their most-recent prior screening mammogram.
• Participants must be asymptomatic for breast disease and undergoing routine screening.
• Participants must not have untreated breast cancer (DCIS or invasive cancer) or currently undergoing treatment for breast cancer or planning surgery for a high risk lesion (atypical ductal breast hyperplasia \[ADH\], atypical lobular breast hyperplasia \[ALH\], lobular breast carcinoma in situ \[LCIS\], papilloma, radial scar) at the time of enrollment.
• Participants on Tamoxifen can be enrolled in registry trial.
• BRCA, other genetic mutation carriers or relatives of mutation carriers, and participants at high-risk for breast cancer, as defined by the American Cancer Society (ACS) breast MR screening recommendations (lifetime risk of >= 20-25%), can participate. These participants may be analyzed as subsets.
• Participants must be able to undergo breast MRI with contrast enhancement; Participants unable to undergo breast MRI with contrast enhancement for any reason are ineligible.
• No history of untreatable claustrophobia
• No presence of non-MRI compatible metallic objects or metallic objects that, in the opinion of the radiologist, would make MRI a contraindication
• No history of sickle cell disease
• No contraindication to intravenous contrast administration
• No known allergy-like reaction to gadolinium or moderate or severe allergic reactions to one or more allergens as defined by the American College of Radiology (ACR); participants may be eligible if willing to undergo pre-treatment as defined by the institution's policy and/or ACR guidance
• No known or suspected renal impairment; requirements for glomerular filtration rate (GFR) prior to MRI as determined by local site standard practice
• Weight less than or equal to the MRI table limit
• Ability to understand and willingness to sign a written informed consent document

Exclusion criteria

• metastatic breast cancer
• medically unstable
• known contraindications to MRI
• allergic reactions to paramagnetic contrast agent or severe allergic diathesis
• on renal dialysis or renal dysfunction
• undergone chemotherapy or hormonal therapy for cancer in previous 6 months
• breast surgery or radiotherapy for cancer to the ipsilateral breast within the past 6 months
• had a history of serious breast trauma within the past 3 months
• pregnant or breastfeeding
• have a disability preventing MRI in a prone position
• some MR conditional implants such as neurostimulators or cardiac monitors, per institutional procedures and policy.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model

Cohort

Study locations

United States · 1 center

• MD Anderson Cancer Center — Houston

Identifiers

NCT: NCT06127797 · 2023-0618 · NCI-2023-08950

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗